What is the current Hydroxychloroquine Drugs Market size?

The Hydroxychloroquine Drugs Market is projected to register a CAGR of 16.80% during the forecast period (2024-2029) Read More

Who are the key players in Hydroxychloroquine Drugs Market?

Sanofi S.A, Sun Pharmaceutical Industries Ltd., Mylan N.V, Teva Pharmaceuticals USA, Inc and Zydus Pharmaceuticals are the major companies operating in the Hydroxychloroquine Drugs Market. Read More

Which is the fastest growing region in Hydroxychloroquine Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Hydroxychloroquine Drugs Market?

In 2024, the North America accounts for the largest market share in Hydroxychloroquine Drugs Market. Read More

What years does this Hydroxychloroquine Drugs Market cover?

The report covers the Hydroxychloroquine Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Hydroxychloroquine Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Hydroxychloroquine Drugs Market Size & Share Analysis - Industry Research Report

Hydroxychloroquine Drugs Industry Overview

Manufacturers offering generic versions dominate the global hydroxychloroquine drugs market. Companies are focusing on building generic chemical entities and innovative molecules to consolidate their foothold. Some of the prominent market participants are DR. REDDY'S LABORATORIES LTD, Laurus Labs Limited, Lupin, Mylan NV, Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc., and Zydus Pharmaceuticals.

The introduction of generic versions and the strong clinical pipeline is anticipated to increase competition in the market. For instance, in April 2020, Zydus Cadila and Ipca Labs have backward integrated HCQ making capability with the aim to increase production capacity by 5-6 times to 70 MT per month thereby, expanding the range of treatment options for the millions of patients living with target diseases.